| Stroke in China. | |
| | |
MedLine Citation:
|
PMID: 19769611 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. Following rapid economic development in China, the epidemiological characteristics, management and prevention strategies for stroke are changing. In the present article, we review recent epidemiological data, as well as studies into the management and prevention of stroke in China. 2. The main findings of the studies reviewed suggest that stroke mortality in China has been reduced significantly. The percentage of haemorrhagic strokes in China is significantly higher than that reported in Western countries. The incidence and subtype of stroke varied widely in different regions in China. Some of the modifiable risk factors for stroke are on the increase in China, including hypertension. 3. Management of stroke is slowly being developed and standardized, as evidenced by the establishment of stroke units and improvements in emergency care. Studies on primary and secondary stroke prevention remain insufficient. Well-designed epidemiological surveys and clinical trials for stroke prevention and management are urgently needed in China. |
| | |
Authors:
|
Qian Jia; Li-Ping Liu; Yong-Jun Wang |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2009-09-21 |
Journal Detail:
|
Title: Clinical and experimental pharmacology & physiology Volume: 37 ISSN: 1440-1681 ISO Abbreviation: Clin. Exp. Pharmacol. Physiol. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-24 Completed Date: 2010-06-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0425076 Medline TA: Clin Exp Pharmacol Physiol Country: Australia |
Other Details:
|
Languages: eng Pagination: 259-64 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Alcohol Drinking / adverse effects, epidemiology Anticoagulants / therapeutic use Antihypertensive Agents / therapeutic use Brain Ischemia / drug therapy China / epidemiology Clinical Trials as Topic Female Glucose / metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hypertension / drug therapy, epidemiology Incidence Male Middle Aged Platelet Aggregation Inhibitors / therapeutic use Randomized Controlled Trials as Topic Risk Factors Smoking / adverse effects, epidemiology Stroke / drug therapy, epidemiology*, etiology Tissue Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Antihypertensive Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors; 50-99-7/Glucose; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lowering of blood pressure during chronic suppression of central sympathetic outflow: Insight from c...
Next Document: Hydrogen sulphide protects H9c2 cells against chemical hypoxia-induced injury.